Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters

Fig. 5

a Representative flow cytometry data demonstrating the gating strategy used on PBMC for CD8+ T cells. FSC-area vs. FSC-height was used for doublet discrimination. A “dump” channel was then used to gate out dead cells (LIVE/DEAD fixable viability stain), CD14+ monocytes, and CD19+ B cells, and lymphocytes were selected by FSC vs. SSC. CD8+ T cells were subsequently selected on the basis of CD8 vs. CD3 staining, followed by the identification of proliferating (Ki67+) or activated (ICOS+) cells, and “effector CD8” cells as HLA-DR+CD38+. b Longitudinal empirical data, linear mixed models and estimated means (left, centre and right-hand panels respectively) for Ki67+ and ICOS+ CD8+ T cells, and HLA-DR+CD38+ effector CD8+ T cells (P-values: * <0.05, ** <0.01, *** <0.001, **** < 0.0001)

Back to article page